USP40通过去泛素化c-MYC促进急性髓系白血病增殖并抑制凋亡，揭示其作为潜在治疗靶点的机制。 泛素特异性肽酶40（USP40）属于去泛素化酶家族，调控多种细胞过程。近期研究日益强调USP40在癌症发展中的作用。然而，USP40影响急性髓系白血病（AML）进展的具体机制 ...

本研究针对T细胞急性淋巴细胞白血病（T-ALL）缺乏有效靶向疗法的临床难题，系统探讨了代谢酶ASS1在T-ALL中的功能与机制。研究发现ASS1在T-ALL中显著高表达且与不良预后相关，通过体内外实验证实ASS1缺失可抑制白血病细胞增殖并诱导凋亡。机制上，ASS1通过维持 ...

--First data disclosure from Ribometrix’s RNA-targeting drug discovery platform identifies small molecules targeting c-MYC, a validated but historically undruggable cancer driver -- --Data shows ...

UTR Therapeutics Inc. has submitted an IND application to the FDA for UTRxM1-18, a novel therapeutic approach for targeting c-MYC-driven cancers. Pending approval, a first-in-human phase I trial is ...

Unless otherwise listed, all solvents and reagents were purchased from Aldrich Chemical Co. (MO, USA) and used as received. Anhydrous chloroform and methanol were purchased from Aldrich Chemical Co.